KRYSTAL-7: Adagrasib Monotherapy or in Combination With Pembrolizumab as First Line Treatment for KRAS G12C Mutant NSCLC
Condition: Non-Small Cell Lung Cancer
Sponsor: Mirati Therapeutics Inc.
849-007: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab plus Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
Oral KRAS G12C inhibitor adagrasib alone or in combination with pembrolizumab
Advanced or metastatic KRAS G12C mutant, PD-L1 TPS <1% non-small cell lung cancer that has not yet been treated in the metastatic setting.
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.